Beam Therapeutics (BEAM) executive compensation, 2026 proxy

John Evans, CEO, was paid $5.8M in 2025, down 9% from $6.4M the year before. The CEO-to-median-employee pay ratio was 22:1, on median employee pay of $264,185.

Filed
April 17, 2026
Annual meeting
June 3, 2026
Pay year
2025
Named executives
5
CEO total pay
$5.8M-9% vs prior year
CEO to median employee
22:1median $264,185
CEO pay in equity
75%$4.4M in awards
CEO Total Compensation
$5,818,525Decreased from prior year
Pay Ratio
22:1CEO to median employee
Median Employee Pay
$264,185Annual total compensation

How Evans was paid

$5.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary13%Stock awards26%Option awards49%Non-equity incentive11%All other compensation0%

Named executive officers

ExecutiveTotal
John EvansCEO$5,818,525
Giuseppe Ciaramella, Ph.D.President$3,160,279
Sravan K. EmanyCFO$1,296,528
Christine Bellon, Ph.D.CLO$1,967,177
Amy Simon, M.D.CMO$2,802,044

What changed and why

  • $5.8MCEO total compensation decreased to $5,818,525 in 2025 from $6,409,631 in 2024.
  • $325KSravan K. Emany received a signing bonus of $325,000 upon joining as CFO.
  • Annual cash incentives were awarded based on the attainment of corporate performance goals.
  • Equity awards were granted in the form of stock options and restricted stock units.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.